Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Italian pharmaceutical firm Abiogen Pharma has signed a license, distribution and supply agreement with China-based Lee's Pharm to market Attila (Neridronic Acid) across China, Hong Kong, Macau and Taiwan.
Subscribe to our email newsletter
As per the deal, Abiogen granted Lee’s Pharm an exclusive license and right for registering, importing, marketing, distributing and selling Attila in the territory, for the two orphan/rare disease indications Osteogenesis Imperfecta (OI) and Complex Regional Pain Syndrome (CRPS).
Currently, neridronate is the only therapeutic agent approved in the world for orphan diseases such as OI and CRPS.
Attila is registered in Italy and is used by patients in 32 European countries under the trade name of Nerixia.
The company said that neridronate demonstrated superior safety profile in long-term use and is highly tolerated by adults and pediatric population.
Abiogen Pharma president and CEO Massimo Di Martino said, "Our partnership with Lee’s Pharm will help patients in mainland China and Taiwan to fight critical rare diseases for which there is no other treatment option available."
Lee’s Pharm chief executive officer Benjamin Li said the company is happy with the partnership with Abiogen Pharma, and excited about the opportunity to work on Neridronate in its territory.
"This is the fourth orphan drug we have licensed-in and it again demonstrates our commitment to rare diseases," Li said.
Attila, an aminobisphosphonate developed and owned by Abiogen Pharma, is the only bisphosphonate indicated for use in neonates and children.